We are fully operational and experiencing no delays
These are very challenging times for us all. We are committed to fully maintaining our operations while protecting the safety of our employees and our community. Most of our team is continuing their work from home. ActX is fully operational and available if you need help. We are actively seeking to help the medical community during this crisis.
COVID-19 susceptibility – based on your genetics
We have added a COVID-19 tab to our patient profile, showing how your likelihood of contracting the virus is affected by your genetics. We created this section based on the latest research, and we will continue to update it as our knowledge evolves. To learn more about your personal COVID-19 risk, sign up for ActX today.
Many healthcare providers have begun using telemedicine in response to the COVID-19 crisis. ActX makes it easy to use virtual appointments. ActX testing is done using kits sent directly to the patient’s house. Patients can access their results online using the ActX portal and smartphone application.
Medication therapy for COVID-19
While no medication has been approved for COVID-19 treatment (and no medication has yet been proven to work) there are on-going discussions about potentially useful medications.
Treatment of infections from the novel coronavirus primarily focuses on isolation and supportive care. As noted by the CDC
, there are several investigational drug therapies for COVID-19, where pharmacogenomics is important. There is not yet sufficient evidence to show efficacy, and the use is unlabeled. If their use is contemplated, pharmacogenomics can be important for chloroquine and hydroxychloroquine therapy, which have been used in combination with azithromycin, and lopinavir/ritonavir.
The relevant genetic conditions are Long QT syndrome (acquired and congenital) and glucose-6-phosphate dehydrogenase (G6PD) deficiency. ActX testing includes variants that are associated with these conditions.
- Chloroquine and hydroxychloroquine were once commonly used for treatment of malaria. Hydroxychloroquine is currently used for certain inflammatory conditions. They are a known risk for Torsades de Pointes (TdP), and it is recommended to avoid these drugs in individuals with congenital or acquired long QT syndrome. The relevant risk is syncope and sudden death. In addition, these two drugs can cause hemolytic anemia in individuals with G6PD deficiency.
- Azithromycin is a macrolide antibiotic. It is also a known risk of TdP, and it is recommended to avoid this drug in individuals with congenital or acquired long QT syndrome.
- Lopinavir/ritonavir is commonly used in treatment of HIV infections. This combination is a possible risk of TdP, and it is recommended to avoid it in individuals with congenital or acquired long QT syndrome.
- CredibleMeds at the Arizona Center for Education and Research on Therapeutics - https://www.crediblemeds.org/new-drug-list/
- US Food and Drug Administration’s Table of Pharmacogenomic Biomarkers in Drug Labeling - https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
- CDC possible therapeutic agents for COVID-19 - https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html